Your Medication Isn't Working. Your Genes May Be Why.

CYP2D6 is one of your liver’s most important drug-metabolizing enzymes. Its job is to break down roughly 25% of all medications you’ll ever take, including antidepressants like venlafaxine and fluoxetine, pain medications like codeine and tramadol, heart medications like metoprolol and propranolol, and a long list of psychiatric medications. Without functioning CYP2D6, none of these drugs get properly cleared from your system.

The problem is that CYP2D6 comes in many variants. Some people carry slow versions (*2, *4, *10, *17) that reduce enzyme activity by 50-90%. Others carry gene duplications that make them ultra-rapid metabolizers. Poor metabolizers represent roughly 7-10% of people with European ancestry, though rates vary significantly by ethnic background. In poor metabolizers, standard medication doses accumulate to toxic levels in the bloodstream, causing severe side effects at doses that work fine for others.

If you’re a CYP2D6 poor metabolizer taking an antidepressant, you might experience tremors, confusion, nausea, or emotional blunting at doses that are considered safe. If you’re taking codeine for pain, your body can’t convert it into its active form, so you feel no relief. Your doctor sees a patient who isn’t improving and assumes the medication doesn’t work for you, when the real problem is that your body can’t process it.

CYP2C19 is critical for activating clopidogrel (Plavix), one of the most prescribed antiplatelet medications after heart attacks and stents. CYP2C19 also metabolizes proton pump inhibitors (omeprazole, pantoprazole), many antidepressants, and a range of other medications. The enzyme’s job is straightforward: convert inactive drug forms into active ones, and break down others for elimination.

Poor metabolizer variants (*2, *3) are carried by roughly 2-15% of the population, depending on ancestry. In poor metabolizers, clopidogrel never gets activated, leaving you without antiplatelet protection after a stent or heart attack despite taking the medication daily. This creates silent clot risk. Meanwhile, ultra-rapid metabolizers metabolize the drug so quickly they have excessive bleeding risk. Neither group gets the therapeutic sweet spot.

You could be taking clopidogrel for months, believing you’re protected, while your genetic profile leaves you completely vulnerable to thrombosis. Standard blood tests won’t reveal this. Your cardiologist has no way of knowing your metabolizer status without genetic testing. The medication doesn’t fail; your metabolism doesn’t match the drug’s design.

CYP2C9 breaks down warfarin, one of the most prescribed blood thinners for atrial fibrillation and clotting disorders. It also metabolizes NSAIDs like ibuprofen and naproxen, as well as some statins. The enzyme’s job is to deactivate these medications so they can be eliminated from your body. Without proper CYP2C9 function, doses linger far too long.

Slow variants (*2, *3) are carried by roughly 5-10% of people with European ancestry. Poor metabolizers of CYP2C9 process warfarin 30-50% more slowly than normal metabolizers. Standard warfarin doses can cause serious bleeding in CYP2C9 poor metabolizers, even when their INR looks controlled on paper. Your doctor adjusts warfarin based on INR values, but if your gene variant makes you a poor metabolizer, a standard dose accumulates dangerously in your system.

You might be bleeding from your gums, seeing blood in your urine, or developing bruises you can’t explain. Your doctor checks your INR and sees it’s in range, which confuses the picture. The problem isn’t your INR; it’s that your genes process warfarin too slowly, and you need a lower baseline dose to stay safe.

VKORC1 encodes the enzyme that recycles vitamin K in your liver. Vitamin K is essential for activating clotting factors. When you take warfarin, it blocks VKORC1, preventing vitamin K recycling and stopping clot formation. The sensitivity of your VKORC1 enzyme to warfarin’s blocking effect is largely genetic. Some people’s VKORC1 is highly sensitive to warfarin; others’ is resistant.

The common -1639G>A variant appears in roughly 40% of people with European ancestry. People carrying the A allele have highly sensitive VKORC1, meaning warfarin has a much stronger anticoagulant effect at standard doses. They achieve therapeutic INR levels at lower warfarin doses than people without the variant. Their vitamin K recycling is naturally less efficient, so blocking it with warfarin creates immediate anticoagulation.

If you carry the sensitive VKORC1 variant and are prescribed standard warfarin doses, you’ll likely overshoot your target INR quickly, increasing bleeding risk. You might bleed easily, develop nosebleeds, or have heavy menstrual bleeding. Conversely, if you’re a resistant metabolizer, standard doses undershoot your therapeutic INR and leave you vulnerable to clots. Neither situation should require trial and error; your genes predict it exactly.

SLCO1B1 encodes a transporter protein that brings statins into liver cells, where they do their job of lowering cholesterol. Statins are some of the most prescribed medications in the world, used to prevent heart attacks and strokes. For statins to work, they need to enter liver cells efficiently. SLCO1B1 controls that delivery. Without functioning SLCO1B1 transporters, statins linger in your bloodstream instead of reaching the liver.

The rs4149056 C allele is carried by roughly 15% of the population. People with this variant have reduced statin transporter activity, meaning statins don’t enter liver cells efficiently. Statins accumulate to higher levels in the bloodstream, increasing the risk of statin myopathy,muscle pain, weakness, and in severe cases, rhabdomyolysis. The risk is highest with simvastatin and atorvastatin, lower with pravastatin and rosuvastatin, which don’t rely on SLCO1B1 as heavily.

You take a standard statin dose and develop muscle pain, fatigue, or weakness a few weeks in. Your doctor might blame age or overexertion. You stop the statin and the symptoms resolve. Your doctor concludes you can’t tolerate statins. But the real issue is that your SLCO1B1 variant created statin accumulation. Switching to a statin that doesn’t require SLCO1B1, or reducing your dose, would have worked perfectly.

TPMT metabolizes thiopurine drugs like azathioprine and 6-mercaptopurine, used to suppress the immune system in autoimmune diseases like Crohn’s disease and lupus, as well as in childhood leukemia treatment. These are powerful, necessary medications, but they’re also toxic at high levels. TPMT’s job is to break down thiopurines so they don’t accumulate. Without adequate TPMT activity, thiopurine metabolites poison bone marrow and cause catastrophic drops in white and red blood cell counts.

TPMT poor metabolizers represent roughly 0.3% of the population overall, though rates vary by ancestry. Intermediate metabolizers are more common. In poor metabolizers, standard thiopurine doses accumulate to toxic levels, causing severe bone marrow suppression, anemia, and immune collapse within weeks. This isn’t a minor side effect; it’s a medical emergency. Patients who are poor metabolizers of TPMT need doses 5-10 times lower than normal metabolizers, or the drug should be avoided altogether.

Without TPMT testing, a patient might start thiopurine therapy on standard dosing and land in the hospital two weeks later with a white blood cell count near zero. Their immune system is destroyed. The medication saved their life, but the dose was lethal. TPMT testing prevents this entirely by identifying poor metabolizers upfront so doses can be adjusted or alternatives chosen.